Redsky, good day to you. I'm sort of in your camp when it comes to fcpg and financing. IMO they most likely have identified a couple of resources for funding, but like everything else, is totally dependent upon successful filings. No matter what scenario is drawn up, the implementation of the new fcpg is satisfied with numbers.
As to other firms taking over fcpg, or taking a significant position in fcpg at current pps levels, without the filings it would not make much sense. It can be done, and there might be conversations underway. It's going to come down to timing and at what pps level is deemed acceptable. To be clear, IMO, a pps of up to .25 will be a buy once numbers are released and they show stability in revenue in years 2012-2013. What many need to recognize, to take control of fcpg you don't need to have 50.1% of the stock. Not exactly sure what the percent would be, but potentially 30% would do it on the open market and nothing wang can do about. It's a cheap way to gain control of a company like fcpg. Another interest of mine once we see day light, is if the private placement holders will move to acquire large amount of shares to literally leverage their output to date. Offshore concerns are waiting ringside too.
Unless I'm totally clueless, a good possibility too, the volume of shares traded upon any filings can dramatically change the entire landscape. I've put my hat in this arena for a long time for the sole reason fcpg can't grow fast enough to keep pace with the pharma market itself. A small revenue producing company like fcpg will be very attractive for other concerns with cash on hand, and need immediate increase in market share. David
News 
Market Data 
Discover 
